Liquidia Corporation (LQDA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Liquidia Corporation (LQDA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.37

-0.39 (-3.32%)

At close: Jan 14, 2025, 3:59 PM

11.36

-0.09%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	11.4
Market Cap	962.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.62
PE Ratio (ttm)	-7.02
Forward PE	n/a
Analyst	Buy

Ask	12.31
Volume	444,120
Avg. Volume (20D)	785,054
Open	11.77
Previous Close	11.76
Day's Range	11.37 - 11.88
52-Week Range	8.26 - 16.99
Beta	undefined

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisvill...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 26, 2018

Employees 145

Stock Exchange NASDAQ

Ticker Symbol LQDA

Website https://www.liquidia.com

Analyst Forecast

According to 8 analyst ratings, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 137.47% from the latest price.

Buy 75.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Liquidia Corporation is scheduled to release its earnings on Mar 12, 2025, before market opens.
Analysts project revenue of $4.44M, reflecting a -2.01% YoY shrinking and earnings per share of -0.4, making a -4.76% decrease YoY.

Why Price Moved

3 months ago · Source

+11.17%

Liquidia Corp shares are trading higher after the ... Unlock content with Pro Subscription

4 months ago · Source

+14.04%

Liquidia shares are trading higher after the company announced it raised $67.5 million from the common stock financing of 6,460,674 shares at $8.90 per share.

News

6 days ago · https://thefly.com

Liquidia named a top pick for 2025 at Needham

Needham analyst Serge Belanger named Liquidia a top pick for 2025 with a Buy rating and $19 price target. The stock was also the analyst's top pick for 2024, and "disappointed" with a negative 2% perf...

1 month ago · zacks.com

Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect?

The mean of analysts' price targets for Liquidia Technologies (LQDA) points to a 132.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

1 month ago · zacks.com

Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High?

The consensus price target hints at a 126.1% upside potential for Liquidia Technologies (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

2 months ago · seekingalpha.com

Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off

Liquidia's Yutrepia, a competitor to United Therapeutics' Tyvaso, faces potential market entry in 2025, with promising clinical data and a competitive therapeutic profile. Despite financial challenges...

2 months ago · seekingalpha.com

Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript

Liquidia Corporation (NASDAQ:LQDA ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty ...

2 months ago · zacks.com

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.

2 months ago · zacks.com

Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Liquidia Technologies (LQDA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.